Gustavo Werutsky, Executive Director at Latin American Cooperative Oncology Group (LACOG), shared on X:
“Today at ESMO2026 in Madrid, I present quality-of-life and patient-reported outcomes from the Phase III lidERA trial of giredestrant in early ER+/HER2- breast cancer. Understanding tolerability is key in adjuvant endocrine therapy, where adherence drives effectiveness.
Rapid Oral Session 538RO: Giredestrant in Early Breast Cancer: Insights into Patients Quality of Life
Abstract: Patient-reported outcomes from the phase III lidERA trial of giredestrant in early breast cancer.
Friday, October 23
4:20 PM.”
You may also find this interesting:
20 Posts Not to Miss from ESMO Congress 2026: Day 1
